CGT Research
Biotechnology-based drugs have been developed and approved rapidly; in recent years, biotechnology-based drugs have entered the clinical phase at an extremely fast pace, becoming the most active field in pharmaceutical R&D. The development, preclinical research (e.g., drug activity and drug stability), and production these drugs are all dependent on cells, especially for cellular immunotherapies such as stem cell reinfusion, cell exosome reinfusion, chimeric antigen receptor T Cell therapy, tumor-Infiltrating lymphocyte (TIL) therapy, engineered T-cell receptor (TCR) therapy, and natural killer (NK) cell therapy. Many cells (such as T lymphocytes, B lymphocytes, monocytes, NK cells, macrophages, dendritic cells, and hepatocytes) are required for in-vitro efficacy evaluation and production of these drugs.
Therefore, cells and cell-related products have an important position in the R&D of new biotechnology drugs and providing them for enterprises and research institutions has become the key to the promotion of biotechnology-based drug development. Unfortunately, these products have long been monopolized by few suppliers and have posed great challenges such as high cost, inflexible procurement, and inconsistent product quality.
In response to the situation, IPHASE offers cells and related products which can meet the demand and show performance comparable to various imported brands. We proactively respond to our customers and provide high-quality services, laying a solid foundation for parallel substitution.
Using iSepTM magnetic beads coupled with highly specific antibody or antibody complex, T cells (CD3+, CD4+, CD8+), B cells (CD19+, CD20+, CD138+), NK cells (CD 56+) and other immune cell subsets are obtained with minimal cellular damage. Cells are released from beads using release buffer for downstream cell culture, flow cytometry analysis and cell-based assays. Isolated primary cells can also be frozen using IPhaseCyroTM buffer for long-term storage in liquid nitrogen.